Q 3856
Q !!Hs1Jq13jV6 ID: df18d2 No.8113297
Feb 12 2020 11:45:18 (EST)
The lines are drawn.
[Zw7301-&vQ-00-00-03]
Define Renegade [Hussein USSS code name].
Standard definition.
Define Evergreen [HRC USSS code name]
Non-standard defintion.
Think depopulation.
The Silent War continues…
Q
Think depopulation.
anon may have solved POTUS' clues.
>>8690876 p.b.
“The hidden scourge”
the eugenics review
1917
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2942223/
>>8689148 p.b.
>Re: 1917 and sex trafficking
>Days before Mr. Epstein hanged himself in a Manhattan jail cell on Aug. 10, he amended his will and named Mr. Nikolic as a fallback executor in the event that one of the two primary executors was unable to serve. (Mr. Nikolic has declined in court proceedings to serve as executor.)
>Mr. Nikolic, who is now running a venture capital firm with Mr. Gates as one of his investors,
Boris Nikolic, Managing Director, Biomatics Capital
Dr. Nikolic is a physician and investor who previously served as chief advisor for science and technology to Bill Gates, leading select for-profit and not-for-profit investment activities. His investments spanned the life science, information technology and health care sectors, including companies such as Foundation Medicine, ResearchGate, Schrodinger and Nimbus Therapeutics. Dr. Nikolic completed postdoctoral training in transplantation immunology at Harvard Medical School and served as an assistant professor of medicine at Massachusetts General Hospital/Harvard Medical School. He has authored more than 70 articles, patents and patent applications, and has co-founded several biotechnology companies that have since been acquired. Dr. Nikolic earned his M.D. from University of Zagreb School of Medicine in Croatia, and clinical training at University Hospital Centre in Zagreb.
https://www.berggruen.org/people/boris-nikolic/
Biomatics Capital Partners, a Seattle, WA-based venture capital firm investing in innovation at the intersection of health care and technology, closed its first fund, at $200m.
Investors include a mix of family offices, institutions and individuals.
Biomatics’ current portfolio includes:
– AiCure (medication adherence powered by artificial intelligence),
– Aledade (data-driven business model for accountable health care),
– BlackThorn Therapeutics (informatics-driven drug discovery),
– Blue Talon (enterprise-level data security for health care),
– Denali Therapeutics (next-gen therapeutics for neurodegenerative diseases),
– GRAIL (genomics-based cancer screening),
– Omniome (low-cost DNA sequencing platform) and
– Twist Bioscience (synthetic DNA).
http://www.finsmes.com/2017/03/biomatics-capital-partners-closes-first-venture-capital-fund-at-200m.html